CMHC Exhibitor Showcase

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym^® (mifepristone) 300mg Tablets, a first generation GR antagonist, for the control of hyperglycemia associated with persistent Cushing syndrome is the company's first FDA-approved medication. www.corcept.com.